Raymond James Financial Services Advisors, Inc. Cv Rx, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	SELL	$8.57 - $15.44 $674,441 - $1.22 Million	-78,698 Reduced 62.34%	47,539 $734,000
Q1 2023 Apr 14, 2023	BUY	$7.08 - $19.4 $509,958 - $1.4 Million	72,028 Added 132.87%	126,237 $1.18 Million
Q4 2022 Feb 08, 2023	BUY	$8.94 - $18.35 $119,965 - $246,238	13,419 Added 32.9%	54,209 $994,000
Q3 2022 Oct 25, 2022	BUY	$6.12 - $9.5 $249,634 - $387,505	40,790 New	40,790 $381,000

Others Institutions Holding CVRX

# of Institutions

Shares Held

14.4M

Call Options Held

56.3K

Put Options Held

41.8K

Johnson & Johnson New Brunswick, NJ

4.1M
Shares

$70.7 Million
11.52% of portfolio
Nea Management Company, LLC Timonium, MD

2.37M
Shares

$40.8 Million
1.6% of portfolio
Black Rock Inc. New York, NY

876K
Shares

$15.1 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

824K
Shares

$14.2 Million
0.0% of portfolio
Parkman Healthcare Partners LLC Stamford, CT

683K
Shares

$11.8 Million
0.85% of portfolio

View Full List

About CVRx, Inc.

Ticker CVRX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 20,576,200
Market Cap $355M
Description
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The co...

More about CVRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account